About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Pomalidomide
- Company
- Janssen Research & Development, LLC
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 61 recruiting
Efficacy results: Not yet reported
61 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Sep 24, 2026
Find a Clinical Trial Near Me
See recruiting studies for Pomalidomide and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT02343042
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Not yet reported, Not yet reported Karyopharm Therapeutics Inc 300 participants Est. completion 2027-04 25 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT04068597
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Not yet reported, Not yet reported CellCentric Ltd. 250 participants Est. completion 2027-03-31 39 sites Stand-aloneOther conditions: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell LymphomaView official trial listing → -
Recruiting NCT NCT04234022
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
The Royal Wolverhampton Hospitals NHS Trust 70 participants Est. completion 2027-12 1 siteOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT04508790
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Not yet reported City of Hope Medical Center 29 participants Est. completion 2027-02-14 8 sites Stand-aloneOther conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaView official trial listing → -
Recruiting NCT NCT04643002
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Not yet reported, Not yet reported Sanofi 258 participants Est. completion 2028-04-20 26 sitesOther conditions: Plasma Cell Myeloma RefractoryView official trial listing → -
Recruiting NCT NCT04661137
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Not yet reported Hackensack Meridian Health 96 participants Est. completion 2028-02 2 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT04830137
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Not yet reported Nurix Therapeutics, Inc. 248 participants Est. completion 2027-05 16 sitesOther conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL)View official trial listing → -
Recruiting NCT NCT04902443
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
Not yet reported National Cancer Institute (NCI) 58 participants Est. completion 2027-12-01 1 site Stand-aloneOther conditions: Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated LymphomasView official trial listing → -
Recruiting NCT NCT04910568
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Not yet reported Genentech, Inc. 186 participants Est. completion 2028-12-21 34 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Not yet reported, Not yet reported BeOne Medicines 246 participants Est. completion 2026-11 78 sites Stand-aloneOther conditions: Relapsed/Refractory Multiple MyelomaView official trial listing → -
Recruiting NCT NCT05020236
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Not yet reported Pfizer 893 participants Est. completion 2027-05-31 237 sitesOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT05137054
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Not yet reported Regeneron Pharmaceuticals 317 participants Est. completion 2032-03-24 42 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT05208307
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Not yet reported Emory University 34 participants Est. completion 2028-10-21 1 site Stand-aloneOther conditions: Plasma Cell MyelomaView official trial listing → -
Recruiting NCT NCT05348213
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
Not yet reported Ruijin Hospital 76 participants Est. completion 2025-06-01 1 site Stand-aloneOther conditions: Diffuse Large B Cell LymphomaView official trial listing → -
Recruiting NCT NCT05389423
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Not yet reported National Cancer Institute (NCI) 25 participants Est. completion 2032-06-01 1 site Stand-aloneOther conditions: Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Plasmablastic Lymphoma, B-Cell NeoplasmView official trial listing → -
Recruiting NCT NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Not yet reported Celgene 810 participants Est. completion 2033-11-30 266 sites Stand-aloneOther conditions: Relapsed or Refractory Multiple MyelomaView official trial listing → -
Recruiting NCT NCT05651932
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Not yet reported K36 Therapeutics, Inc. 165 participants Est. completion 2028-06-30 26 sites Stand-aloneOther conditions: Multiple Myeloma, Myeloma, Myeloma MultipleView official trial listing → -
Recruiting NCT NCT05714839
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Not yet reported, Not yet reported GlaxoSmithKline 123 participants Est. completion 2028-08-03 44 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT05730036
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Not yet reported Regeneron Pharmaceuticals 410 participants Est. completion 2033-04-19 159 sitesOther conditions: Relapsed Refractory Multiple Myeloma (RRMM)View official trial listing → -
Recruiting NCT NCT05789303
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Not yet reported University of Chicago 83 participants Est. completion 2028-07-01 2 sites Stand-aloneOther conditions: Multiple Myeloma, Relapse Multiple MyelomaView official trial listing → -
Recruiting NCT NCT05828459
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Not yet reported Onward Therapeutics 150 participants Est. completion 2027-07 4 sites Stand-aloneOther conditions: Hematological Malignancy, Solid TumorView official trial listing → -
Recruiting NCT NCT05922501
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Not yet reported Massachusetts General Hospital 50 participants Est. completion 2030-12-31 2 sites Stand-aloneOther conditions: Relapsed Cancer, Refractory Multiple Myeloma, Multiple MyelomaView official trial listing → -
Recruiting NCT NCT05931328
The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.
Not yet reported The First Affiliated Hospital with Nanjing Medical University 28 participants Est. completion 2026-10 1 site Stand-aloneOther conditions: Relapsed or Refractory (R/R) Primary Central Nervous System LymphomaView official trial listing → -
Recruiting NCT NCT06106945
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Not yet reported, Not yet reported AstraZeneca 226 participants Est. completion 2027-08-16 43 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT06152575
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Not yet reported Pfizer 492 participants Est. completion 2027-12-30 270 sitesOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT06158412
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Not yet reported The First Affiliated Hospital of Xiamen University 25 participants Est. completion 2025-12-31 1 site Stand-aloneOther conditions: Multiple Myeloma in Relapse, Multiple Myeloma, RefractoryView official trial listing → -
Recruiting NCT NCT06246162
Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
Not yet reported, Not yet reported Affiliated Hospital of Nantong University 30 participants Est. completion 2026-11-30 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT06252792
Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
FengYan Jin 50 participants Est. completion 2026-06-15 1 siteOther conditions: Multiple Myeloma, First RelapseView official trial listing → -
Recruiting NCT NCT06342466
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Not yet reported Jin Lu, MD 40 participants Est. completion 2026-12 1 site Stand-aloneOther conditions: Systemic AmyloidosisView official trial listing → -
Recruiting NCT NCT06376214
Daratumumab for Patients With Light Chain Amyloidosis
Not yet reported Nanjing University School of Medicine 100 participants Est. completion 2026-12-31 1 site Stand-aloneOther conditions: Light Chain (AL) AmyloidosisView official trial listing → -
Recruiting NCT NCT06464991
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Not yet reported Nanjing IASO Biotechnology Co., Ltd. 240 participants Est. completion 2030-12 28 sitesOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT06484829
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Not yet reported, Not yet reported Chengdu Zenitar Biomedical Technology Co., Ltd 144 participants Est. completion 2026-04-01 1 site Stand-aloneOther conditions: Relapsed or Refractory Multiple Myeloma (RRMM)View official trial listing → -
Recruiting NCT NCT06508983
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
Not yet reported Hangzhou Sumgen Biotech Co., Ltd. 360 participants Est. completion 2028-03-31 12 sites Stand-aloneOther conditions: Relapsed/Refractory Multiple MyelomaView official trial listing → -
Recruiting NCT NCT06554561
A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma
Not yet reported, Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 43 participants Est. completion 2029-08-31 1 site Stand-aloneOther conditions: PCNSLView official trial listing → -
Recruiting NCT NCT06561854
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Not yet reported Assistance Publique - Hôpitaux de Paris 318 participants Est. completion 2028-12 1 site Stand-aloneOther conditions: Multiple Myeloma, Relapse Multiple MyelomaView official trial listing → -
Recruiting NCT NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Not yet reported Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 440 participants Est. completion 2032-06-22 141 sites Stand-aloneOther conditions: Relapsed or Refractory Multiple Myeloma (RRMM)View official trial listing → -
Recruiting NCT NCT06768489
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Not yet reported Janssen Research & Development, LLC 240 participants Est. completion 2029-06-29 16 sites Stand-aloneOther conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain AmyloidosisView official trial listing → -
Recruiting NCT NCT06855823
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Not yet reported, Not yet reported Sun Yat-sen University 33 participants Est. completion 2026-12 1 site Stand-aloneOther conditions: Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)View official trial listing → -
Recruiting NCT NCT06879379
KPD Consolidation After ASCT in NDMM Patients
Not yet reported, Not yet reported Peking University People's Hospital 202 participants Est. completion 2029-03 3 sites Stand-aloneOther conditions: Multiple Myeloma, Newly DiagnosedView official trial listing → -
Recruiting NCT NCT06948084
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
Not yet reported National Cancer Institute (NCI) 80 participants Est. completion 2028-02-28 1 siteOther conditions: Recurrent Multiple Myeloma, Refractory Multiple MyelomaView official trial listing → -
Recruiting NCT NCT06953960
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Not yet reported, Not yet reported AbbVie 325 participants Est. completion 2030-12 50 sitesOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT07018050
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Not yet reported Qilu Pharmaceutical Co., Ltd. 160 participants Est. completion 2028-07 1 site Stand-aloneOther conditions: Relapsed or Refractory Multiple MyelomaView official trial listing → -
Recruiting NCT NCT07072208
Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL
Not yet reported The First Affiliated Hospital of Soochow University 43 participants Est. completion 2027-05-01 1 site Stand-aloneOther conditions: Diffuse Large B-Cell LymphomaView official trial listing → -
Recruiting NCT NCT07096778
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Not yet reported CellCentric Ltd. 100 participants Est. completion 2029-12-01 31 sites Stand-aloneOther conditions: Multiple Myeloma Refractory, Multiple Myeloma in RelapseView official trial listing → -
Recruiting NCT NCT07138209
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Not yet reported Qilu Pharmaceutical Co., Ltd. 228 participants Est. completion 2029-12 1 site Stand-aloneOther conditions: Relapsed or Refractory Multiple MyelomaView official trial listing → -
Recruiting NCT NCT07222761
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Not yet reported Regeneron Pharmaceuticals 915 participants Est. completion 2034-08-23 24 sites Stand-aloneOther conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM)View official trial listing → -
Recruiting NCT NCT07227311
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Not yet reported GlaxoSmithKline 200 participants Est. completion 2030-08-30 59 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT07257510
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
Not yet reported Peking University Third Hospital 34 participants Est. completion 2028-08-01 1 site Stand-aloneOther conditions: Mantle Cell Lymphoma (MCL), POZView official trial listing → -
Recruiting NCT NCT07312188
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Not yet reported Shandong New Time Pharmaceutical Co., LTD 90 participants Est. completion 2028-05-20 1 siteOther conditions: Relapsed or Refractory Multiple MyelomaView official trial listing → -
Recruiting NCT NCT07391657
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Not yet reported AstraZeneca 508 participants Est. completion 2030-07-29 143 sitesOther conditions: Relapsed Refractory Multiple MyelomaView official trial listing → -
Recruiting NCT NCT07452198
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Not yet reported Genrix (Shanghai) Biopharmaceutical Co., Ltd. 358 participants Est. completion 2030-03 1 siteOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT07463807
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
Not yet reported, Not yet reported National Cancer Institute (NCI) 162 participants Est. completion 2029-03-31 1 site Stand-aloneOther conditions: Recurrent Multiple Myeloma, Refractory Multiple MyelomaView official trial listing → -
Recruiting NCT NCT07523737
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Not yet reported Beijing Tongren Hospital 43 participants Est. completion 2028-08-31 1 site Stand-aloneOther conditions: Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)View official trial listing → -
Recruiting NCT NCT07532525
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Not yet reported University of Michigan Rogel Cancer Center 12 participants Est. completion 2028-10 1 site Stand-aloneOther conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin LymphomaView official trial listing → -
Recruiting NCT NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Not yet reported Hoffmann-La Roche 380 participants Est. completion 2033-01-31 75 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT07579234
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Not yet reported Shandong New Time Pharmaceutical Co., LTD 261 participants Est. completion 2029-01-25 1 siteOther conditions: Relapsed or Refractory Multiple Myeloma (RRMM)View official trial listing → -
Recruiting NCT NCT07623798
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 255 participants Est. completion 2029-12-31 1 siteOther conditions: Relapsed or Refractory Multiple MyelomaView official trial listing → -
Recruiting NCT NCT07742215
A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
Not yet reported Biocad 390 participants Est. completion 2032-10 16 sitesOther conditions: Myeloma MultipleView official trial listing → -
Recruiting NCT NCT07749365
Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
Not yet reported The First Affiliated Hospital of Xiamen University 53 participants Est. completion 2029-12-31 1 site Stand-aloneOther conditions: DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma)View official trial listing → -
Recruiting NCT NCT07772024
Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma
Not yet reported CellCentric Ltd. 450 participants Est. completion 2031-11 1 site Stand-aloneOther conditions: Multiple Myeloma Refractory, Multiple Myeloma in RelapseView official trial listing → -
Recruiting NCT NCT07825064
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
Not yet reported Hoffmann-La Roche 45 participants Est. completion 2031-01-30 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT00072722
Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
Not yet reported Celgene Corporation 36 participants Est. completion 2005-04 2 sitesOther conditions: Prostate CancerView official trial listing → -
Completed NCT NCT00463385
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
Not yet reported Celgene 88 participants Est. completion 2013-12-31 11 sites Stand-aloneOther conditions: Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, MyelofibrosisView official trial listing → -
Completed NCT NCT00482521
CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment
Not yet reported Case Comprehensive Cancer Center 42 participants Est. completion 2012-08 2 sitesOther conditions: Unspecified Adult Solid Tumor, Protocol SpecificView official trial listing → -
Terminated NCT NCT00537511
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide
Not yet reported, Not yet reported Celgene 22 participants Est. completion 2010-12-01 6 sites Stand-aloneOther conditions: Carcinoma, Small CellView official trial listing → -
Completed NCT NCT00540579
CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas
Not yet reported, Not yet reported SCRI Development Innovations, LLC 23 participants Est. completion 2011-01 2 sites Stand-aloneOther conditions: Pancreatic CancerView official trial listing → -
Completed NCT NCT00558896
CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
Not yet reported Mayo Clinic 378 participants Est. completion 2017-10-25 3 sites Stand-aloneOther conditions: Multiple Myeloma and Plasma Cell NeoplasmView official trial listing → -
Completed NCT NCT00669578
CC-4047 in Treating Patients With Myelofibrosis
Not yet reported, Not yet reported Mayo Clinic 77 participants Est. completion 2019-12-12 1 siteOther conditions: Chronic Myeloproliferative Disorders, Secondary MyelofibrosisView official trial listing → -
Terminated NCT NCT00717522
Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma
Not yet reported Celgene 7 participants Est. completion 2009-01-01 3 sites Stand-aloneOther conditions: Soft Tissue SarcomaView official trial listing → -
Completed NCT NCT00770757
CC-4047 (Pomalidomide) for Graft vs. Host Disease
Not yet reported Washington University School of Medicine 13 participants Est. completion 2011-10 1 siteOther conditions: Graft vs Host DiseaseView official trial listing → -
Completed NCT NCT00833833
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
Not yet reported, Not yet reported Celgene Corporation 259 participants Est. completion 2015-09 19 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT00946270
Pomalidomide for Myelofibrosis Patients
Not yet reported M.D. Anderson Cancer Center 70 participants Est. completion 2018-05-22 1 siteOther conditions: Polycythemia Vera, ThrombocythemiaView official trial listing → -
Completed NCT NCT00949364
Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage
Not yet reported University of Ulm 103 participants Est. completion 2016-12-14 15 sites Stand-aloneOther conditions: Myeloproliferative NeoplasmsView official trial listing → -
Completed NCT NCT01053949
IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma
Not yet reported University Hospital, Lille 84 participants Est. completion 2015-04 19 sitesOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT01078974
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
Not yet reported Steven P. Treon, MD, PhD 7 participants Est. completion 2016-03 1 site Stand-aloneOther conditions: Waldenstrom's MacroglobulinemiaView official trial listing → -
Withdrawn NCT NCT01135199
Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis
Not yet reported Stanford University Est. completion 2010-06 1 siteOther conditions: Pulmonary FibrosisView official trial listing → -
Completed NCT NCT01159574
Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
Not yet reported Weill Medical College of Cornell University 121 participants Est. completion 2015-05-05 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01166113
Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide
Not yet reported, Not yet reported Fondazione EMN Italy Onlus 67 participants Est. completion 2023-06 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01177735
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
Not yet reported University of Arkansas 71 participants Est. completion 2013-09 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01178281
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
Not yet reported Celgene 267 participants Est. completion 2018-05-15 87 sites Stand-aloneOther conditions: Primary Myelofibrosis, MPN-associated MyelofibrosisView official trial listing → -
Terminated NCT NCT01198067
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
Not yet reported M.D. Anderson Cancer Center 15 participants Est. completion 2025-05-02 1 site Stand-aloneOther conditions: Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom MacroglobulinemiaView official trial listing → -
Completed NCT NCT01212952
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Not yet reported, Not yet reported Mayo Clinic 50 participants Est. completion 2018-03-22 3 sites Stand-aloneOther conditions: Refractory Multiple MyelomaView official trial listing → -
Completed NCT NCT01243944
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Not yet reported Incyte Corporation 222 participants Est. completion 2018-02-09 102 sitesOther conditions: Polycythemia VeraView official trial listing → -
Completed NCT NCT01311687
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
Not yet reported Celgene 455 participants Est. completion 2017-08-29 94 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01319422
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Not yet reported Yale University 40 participants Est. completion 2014-11 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01324947
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Not yet reported Celgene 74 participants Est. completion 2014-07-31 91 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01421186
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
Not yet reported, Not yet reported MorphoSys AG 91 participants Est. completion 2020-08 10 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01421524
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Not yet reported Celgene 271 participants Est. completion 2023-11-21 39 sites Stand-aloneOther conditions: Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System LymphomaView official trial listing → -
Completed NCT NCT01432600
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
Not yet reported, Not yet reported H. Lee Moffitt Cancer Center and Research Institute 80 participants Est. completion 2016-08 3 sites Stand-aloneOther conditions: MyelomaView official trial listing → -
Terminated NCT NCT01464034
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Not yet reported, Not yet reported Criterium, Inc. 136 participants Est. completion 2020-07 9 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01474330
A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
Not yet reported Celgene 33 participants Est. completion 2011-10-01 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT01495598
Pomalidomide for Kaposi Sarcoma in People With or Without HIV
Not yet reported, Not yet reported National Cancer Institute (NCI) 28 participants Est. completion 2022-05-17 1 site Stand-aloneOther conditions: Kaposi Sarcoma, Sarcoma, KaposiView official trial listing → -
Completed NCT NCT01497093
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Not yet reported Celgene 34 participants Est. completion 2019-07-23 6 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01510613
Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
Not yet reported Fondazione IRCCS Policlinico San Matteo di Pavia 28 participants Est. completion 2016-12 1 site Stand-aloneOther conditions: Primary Amyloidosis of Light Chain TypeView official trial listing → -
Completed NCT NCT01522547
Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease
Not yet reported Celgene 12 participants Est. completion 2013-12-01 1 site Stand-aloneOther conditions: Anemia, Sickle CellView official trial listing → -
Status unknown NCT NCT01522872
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Not yet reported, Not yet reported Threshold Pharmaceuticals 98 participants Est. completion 2017-09 10 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT01537861
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
Not yet reported Washington University School of Medicine 7 participants Est. completion 2014-12 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Status unknown NCT NCT01541332
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
Not yet reported, Not yet reported Oncotherapeutics 70 participants Est. completion 2016-12 8 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT01559129
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease
Not yet reported Celgene 23 participants Est. completion 2016-11-03 56 sites Stand-aloneOther conditions: Scleroderma, Systemic, Sclerosis, Systemic, Systemic Scleroderma, Systemic Sclerosis, Interstitial Lung DiseaseView official trial listing → -
Active, not recruiting NCT NCT01562405
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Not yet reported Massachusetts General Hospital 33 participants Est. completion 2027-12 4 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01568294
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Not yet reported Celgene 12 participants Est. completion 2015-07-08 8 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01570387
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
Not yet reported, Not yet reported Boston Medical Center 27 participants Est. completion 2019-04 1 site Stand-aloneOther conditions: AL AmyloidosisView official trial listing → -
Completed NCT NCT01575925
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)
Not yet reported Celgene 25 participants Est. completion 2018-08-07 9 sitesOther conditions: Multiple Myeloma, Renal ImpairmentView official trial listing → -
Completed NCT NCT01592370
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Not yet reported, Not yet reported Bristol-Myers Squibb 320 participants Est. completion 2024-07-09 43 sites Stand-aloneOther conditions: Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple MyelomaView official trial listing → -
Approved For Marketing NCT NCT01632826
Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma
Celgene 42 sitesOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01638936
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
Not yet reported, Not yet reported Biotest Pharmaceuticals Corporation 64 participants Est. completion 2018-10-30 10 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01644110
Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF
Not yet reported, Not yet reported University of Ulm 96 participants Est. completion 2024-04-27 17 sites Stand-aloneOther conditions: Primary Myelofibrosis, Secondary Myelofibrosis, PMF, SMF, Post-PV MF, Post-ET MFView official trial listing → -
Completed NCT NCT01665794
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Not yet reported, Not yet reported University of Chicago 25 participants Est. completion 2025-11-14 5 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01688466
Pomalidomide for Chronic Graft-versus-Host Disease
Not yet reported National Cancer Institute (NCI) 34 participants Est. completion 2019-05-20 1 site Stand-aloneOther conditions: Graft vs Host Disease, Graft-Versus-Host DiseaseView official trial listing → -
Completed NCT NCT01707407
A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
Not yet reported Celgene 32 participants Est. completion 2012-11-01 1 site Stand-aloneOther conditions: Pharmacology, Clinical, HealthyView official trial listing → -
Completed NCT NCT01712789
Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Not yet reported Celgene 682 participants Est. completion 2019-12-11 112 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01722305
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
Not yet reported Mayo Clinic 29 participants Est. completion 2019-07-15 7 sites Stand-aloneOther conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma, Intraocular Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Recurrent Adult Diffuse Large Cell Lymphoma, Retinal LymphomaView official trial listing → -
Terminated NCT NCT01728259
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Not yet reported Barbara Ann Karmanos Cancer Institute 18 participants Est. completion 2018-10-31 5 sites Stand-aloneOther conditions: Light Chain Deposition Disease, Primary Systemic AmyloidosisView official trial listing → -
Completed NCT NCT01734928
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Not yet reported Celgene 559 participants Est. completion 2022-05-13 321 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01745588
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
Not yet reported Memorial Sloan Kettering Cancer Center 23 participants Est. completion 2025-09-03 10 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01745640
Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)
Not yet reported University Hospital, Lille 63 participants Est. completion 2015-12 20 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Status unknown NCT NCT01754402
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Not yet reported, Not yet reported Cristina Gasparetto 56 participants Est. completion 2025-01-01 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01794039
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide
Not yet reported Mayo Clinic 9 participants Est. completion 2016-11 1 site Stand-aloneOther conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaView official trial listing → -
Terminated NCT NCT01807286
Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
Not yet reported M.D. Anderson Cancer Center 3 participants Est. completion 2016-02 1 site Stand-aloneOther conditions: MyelomaView official trial listing → -
Completed NCT NCT01835561
Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males
Not yet reported Celgene 32 participants Est. completion 2014-08-21 2 sites Stand-aloneOther conditions: Clinical Pharmacology, Healthy Volunteer StudyView official trial listing → -
Terminated NCT NCT01889420
Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Not yet reported New Mexico Cancer Research Alliance 1 participants Est. completion 2015-07 1 site Stand-aloneOther conditions: Multiple Myeloma in RelapseView official trial listing → -
Terminated NCT NCT01946152
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
Not yet reported, Not yet reported M.D. Anderson Cancer Center 21 participants Est. completion 2020-03-18 1 site Stand-aloneOther conditions: Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaView official trial listing → -
Completed NCT NCT01946477
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
Not yet reported Celgene 186 participants Est. completion 2025-05-26 49 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT01979276
Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
Not yet reported, Not yet reported Weill Medical College of Cornell University 4 participants Est. completion 2016-10 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01986894
A Phase 1 QT Study in Healthy Male Subjects
Not yet reported Celgene 72 participants Est. completion 2013-12-02 1 site Stand-aloneOther conditions: Clinical Pharmacology, Healthy Volunteer StudyView official trial listing → -
Terminated NCT NCT01997840
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Not yet reported, Not yet reported Celgene 103 participants Est. completion 2024-02-29 2 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT01998971
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Not yet reported Janssen Research & Development, LLC 240 participants Est. completion 2024-01-11 22 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT01999335
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
Not yet reported Amgen 33 participants Est. completion 2019-04-25 17 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Status unknown NCT NCT02004275
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
Not yet reported, Not yet reported Alliance for Clinical Trials in Oncology 118 participants 336 sites Stand-aloneOther conditions: Multiple Myeloma in RelapseView official trial listing → -
Completed NCT NCT02011113
Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
Not yet reported Celgene Corporation 36 participants Est. completion 2015-09 14 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02029950
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Not yet reported National Cancer Institute (NCI) 50 participants Est. completion 2020-05-13 3 sites Stand-aloneOther conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia-2, High Risk Myelodysplastic Syndrome, Myeloproliferative NeoplasmView official trial listing → -
Completed NCT NCT02045017
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
Not yet reported Celgene 81 participants Est. completion 2021-07-28 22 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02046915
Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide
Not yet reported University Hospital Tuebingen 60 participants Est. completion 2017-08-17 1 site Stand-aloneOther conditions: Relapsed or Refractory Multiple MyelomaView official trial listing → -
Completed NCT NCT02071888
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
Not yet reported Calithera Biosciences, Inc 25 participants Est. completion 2016-04 7 sites Stand-aloneOther conditions: Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM, T-cell NHLView official trial listing → -
Completed NCT NCT02075996
Non-interventional Study With Pomalidomide (Imnovid®)
iOMEDICO AG 151 participants Est. completion 2021-02-04 1 siteOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02103335
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
Not yet reported Celgene 38 participants Est. completion 2016-11-30 6 sites Stand-aloneOther conditions: Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Multiple MyelomaView official trial listing → -
Completed NCT NCT02119468
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Not yet reported, Not yet reported City of Hope Medical Center 32 participants Est. completion 2022-12-01 5 sites Stand-aloneOther conditions: Refractory Plasma Cell Myeloma, Recurrent Plasma Cell MyelomaView official trial listing → -
Withdrawn NCT NCT02155634
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
Not yet reported Celgene Est. completion 2021-03Other conditions: Multiple Myeloma, Neoplasms, Plasma Cells, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Therapeutic UsesView official trial listing → -
Status unknown NCT NCT02158702
Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib
Not yet reported National University Hospital, Singapore 100 participants Est. completion 2018-11 2 sites Stand-aloneOther conditions: Multiple Myeloma, Relapse After Use of Lenalidomide and BortezomibView official trial listing → -
Completed NCT NCT02164955
A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.
Celgene 775 participants Est. completion 2022-10-10 122 sitesOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02168205
Food Effect and CYP1A2 Induction Study in Healthy Subjects
Not yet reported Celgene 55 participants Est. completion 2014-09-19 1 site Stand-aloneOther conditions: Healthy VolunteersView official trial listing → -
Completed NCT NCT02176213
Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Not yet reported Ajai Chari 35 participants Est. completion 2019-05-07 1 site Stand-aloneOther conditions: Multiple Myeloma in Relapse, Multiple Myeloma, RefractoryView official trial listing → -
Completed NCT NCT02185820
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)
Not yet reported, Not yet reported European Myeloma Network B.V. 57 participants Est. completion 2023-01 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT02188368
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
Not yet reported Oncotherapeutics 45 participants Est. completion 2020-10-23 12 sitesOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02189343
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Not yet reported Celgene 16 participants Est. completion 2018-04-30 3 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02206425
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Not yet reported, Not yet reported Oncotherapeutics 45 participants Est. completion 2018-03-06 12 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Withdrawn NCT NCT02228512
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
Not yet reported, Not yet reported National Cancer Institute (NCI) Est. completion 2015-05-05Other conditions: Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease, Primary Effusion LymphomaView official trial listing → -
Completed NCT NCT02244125
A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)
Not yet reported Institut Curie 100 participants Est. completion 2023-05-29 30 sitesOther conditions: Multiple Myeloma, First RelapseView official trial listing → -
Terminated NCT NCT02265510
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Not yet reported, Not yet reported Incyte Corporation 83 participants Est. completion 2019-02-27 14 sites Stand-aloneOther conditions: Solid Tumors, Advanced Malignancies, Metastatic CancerView official trial listing → -
Completed NCT NCT02283775
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients
Not yet reported Sanofi 54 participants Est. completion 2021-05-26 13 sites Stand-aloneOther conditions: Plasma Cell MyelomaView official trial listing → -
Completed NCT NCT02287558
Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
Not yet reported The Cleveland Clinic 9 participants Est. completion 2019-06-01 1 site Stand-aloneOther conditions: Hereditary Hemorrhagic Telangiectasia, Idiopathic Vascular EctasiaView official trial listing → -
Terminated NCT NCT02289222
1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
Not yet reported, Not yet reported Ashraf Badros 48 participants Est. completion 2017-08-07 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT02294357
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Not yet reported Oncotherapeutics 45 participants Est. completion 2020-09-22 7 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02336815
Selinexor Treatment of Refractory Myeloma
Not yet reported Karyopharm Therapeutics Inc 202 participants Est. completion 2019-07-26 61 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02384083
Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients
Not yet reported, Not yet reported PETHEMA Foundation 47 participants Est. completion 2020-03-23 10 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT02400242
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
Not yet reported Celgene 85 participants Est. completion 2024-06-03 17 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT02406222
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
Not yet reported University of Leeds 124 participants Est. completion 2025-06 21 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02415153
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Not yet reported National Cancer Institute (NCI) 29 participants Est. completion 2020-05-27 12 sites Stand-aloneOther conditions: Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Primary Central Nervous System Neoplasm, Refractory Primary Central Nervous System NeoplasmView official trial listing → -
Completed NCT NCT02431208
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Not yet reported Hoffmann-La Roche 85 participants Est. completion 2021-03-19 31 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT02462525
Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
Not yet reported AbbVie 74 participants Est. completion 2017-12-06 19 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT02542657
Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma
Not yet reported, Not yet reported Joseph Tuscano 30 participants Est. completion 2025-12 3 sites Stand-aloneOther conditions: MyelomaView official trial listing → -
Completed NCT NCT02547662
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Not yet reported Mayo Clinic 17 participants Est. completion 2020-10-30 2 sites Stand-aloneOther conditions: Plasma Cell Leukemia, Plasma Cell Myeloma, PlasmacytomaView official trial listing → -
Terminated NCT NCT02548962
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Not yet reported, Not yet reported Pharmacyclics LLC. 11 participants Est. completion 2018-06-13 16 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02555839
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
Celgene 127 participants Est. completion 2023-06-30 13 sitesOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02569320
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma
Not yet reported Ohio State University Comprehensive Cancer Center 9 participants Est. completion 2021-03-10 1 site Stand-aloneOther conditions: Recurrent Plasma Cell MyelomaView official trial listing → -
Terminated NCT NCT02576977
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
Not yet reported Merck Sharp & Dohme LLC 251 participants Est. completion 2020-07-16 Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Withdrawn NCT NCT02578121
UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
Not yet reported University of Arkansas Est. completion 2017-01 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02612779
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Not yet reported Bristol-Myers Squibb 74 participants Est. completion 2020-06-12 22 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02616640
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Not yet reported Celgene 114 participants Est. completion 2024-07-30 22 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02626481
Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma
Not yet reported University Hospital, Lille 64 participants Est. completion 2020-03-09 41 sitesOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02654132
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Not yet reported Bristol-Myers Squibb 117 participants Est. completion 2021-10-21 55 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT02659930
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
Not yet reported National Cancer Institute (NCI) 62 participants Est. completion 2029-01-01 1 site Stand-aloneOther conditions: Kaposi SarcomaView official trial listing → -
Terminated NCT NCT02661022
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Not yet reported, Not yet reported Stemline Therapeutics, Inc. 9 participants Est. completion 2019-12 3 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT02718833
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Not yet reported Massachusetts General Hospital 52 participants Est. completion 2027-12 6 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02719613
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Not yet reported Bristol-Myers Squibb 67 participants Est. completion 2026-02-23 41 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02726581
An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
Not yet reported Bristol-Myers Squibb 170 participants Est. completion 2022-03-09 121 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT02807454
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
Not yet reported Celgene 37 participants Est. completion 2022-01-03 64 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02900716
Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Not yet reported Zhejiang DTRM Biopharma 48 participants Est. completion 2020-11-23 6 sites Stand-aloneOther conditions: Chronic Lymphocytic Leukemia, B-Cell LymphomaView official trial listing → -
Completed NCT NCT02902900
An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice
Celgene 2504 participants Est. completion 2022-05-31 126 sitesOther conditions: Multiple MyelomaView official trial listing → -
Status unknown NCT NCT02916420
Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma
Not yet reported Jiangsu Simcere Pharmaceutical Co., Ltd. 73 participants Est. completion 2019-06 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02921828
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
Celgene 1149 participants Est. completion 2015-12-10 2 sitesOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02939183
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
Not yet reported Amgen 61 participants Est. completion 2022-10-06 20 sites Stand-aloneOther conditions: Relapsed or Refractory Multiple MyelomaView official trial listing → -
Completed NCT NCT02963493
A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Not yet reported Oncopeptides AB 157 participants Est. completion 2021-11-16 20 sitesOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT02990338
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
Not yet reported Sanofi 307 participants Est. completion 2023-11-01 111 sites Stand-aloneOther conditions: Plasma Cell MyelomaView official trial listing → -
Status unknown NCT NCT03015922
Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma
Not yet reported University of Leeds 4 participants Est. completion 2021-10-01 2 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT03023527
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
Not yet reported PETHEMA Foundation 6 participants Est. completion 2018-01 12 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT03030261
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Not yet reported Washington University School of Medicine 25 participants Est. completion 2027-09-26 3 sites Stand-aloneOther conditions: Multiple Myeloma in RelapseView official trial listing → -
Terminated NCT NCT03104270
Combination Study for High Risk Multiple Myeloma Patients
Not yet reported Oncotherapeutics 13 participants Est. completion 2020-01-23 6 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Status unknown NCT NCT03113942
Study of Pomalidomide in Anal Cancer Precursors
Not yet reported Kirby Institute 26 participants Est. completion 2022-12-31 1 site Stand-aloneOther conditions: High Grade Squamous Intra-epithelial Lesion (HSIL)View official trial listing → -
Status unknown NCT NCT03143049
Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma
Not yet reported National University Hospital, Singapore 120 participants Est. completion 2022-06-01 5 sites Stand-aloneOther conditions: Relapse Multiple MyelomaView official trial listing → -
Completed NCT NCT03143985
Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
Not yet reported Koen van Besien 18 participants Est. completion 2022-09-01 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT03151811
A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
Not yet reported Oncopeptides AB 495 participants Est. completion 2023-02-03 105 sitesOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT03170882
A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
Not yet reported Millennium Pharmaceuticals, Inc. 122 participants Est. completion 2021-11-26 111 sitesOther conditions: Relapsed and/or Refractory Multiple MyelomaView official trial listing → -
Completed NCT NCT03180736
Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex
Not yet reported Stichting European Myeloma Network 304 participants Est. completion 2024-11-30 40 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT03202628
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
Not yet reported Mayo Clinic 8 participants Est. completion 2021-04-13 1 site Stand-aloneOther conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaView official trial listing → -
Completed NCT NCT03215524
A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide
Not yet reported Canadian Myeloma Research Group 120 participants Est. completion 2022-06-24 11 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Withdrawn NCT NCT03227432
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Not yet reported Dana-Farber Cancer Institute Est. completion 2024-12-31 3 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT03242460
The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)
Not yet reported Kosin University Gospel Hospital 55 participants Est. completion 2019-05-02 1 site Stand-aloneOther conditions: Relapsed and/or refractorY Multiple MyelomaView official trial listing → -
Completed NCT NCT03257631
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Not yet reported Celgene 53 participants Est. completion 2023-09-14 22 sites Stand-aloneOther conditions: Central Nervous System Neoplasms, MedulloblastomaView official trial listing → -
Completed NCT NCT03269136
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
Not yet reported Pfizer 101 participants Est. completion 2024-01-19 37 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT03287908
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Not yet reported Amgen 174 participants Est. completion 2023-06-30 34 sites Stand-aloneOther conditions: Relapsed/Refractory Multiple MyelomaView official trial listing → -
Completed NCT NCT03288974
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
Celgene 397 participants Est. completion 2023-11-16 33 sitesOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT03353545
Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life Conditions
Genesis Pharma S.A. 110 participants Est. completion 2020-02-28 1 siteOther conditions: Relapse/Refractory Multiple MyelomaView official trial listing → -
Completed NCT NCT03424928
A Pilot Bioequivalence Study of Pomalidomide
Not yet reported Jiangsu Simcere Pharmaceutical Co., Ltd. 12 participants Est. completion 2018-02-06 1 site Stand-aloneOther conditions: BioequivalenceView official trial listing → -
Completed NCT NCT03439280
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Not yet reported, Not yet reported Millennium Pharmaceuticals, Inc. 50 participants Est. completion 2022-01-28 7 sites Stand-aloneOther conditions: Relapsed/Refractory, Multiple MyelomaView official trial listing → -
Terminated NCT NCT03440411
Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment
Not yet reported Fondazione EMN Italy Onlus 9 participants Est. completion 2019-12-31 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT03477643
Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
PETHEMA Foundation 110 participants Est. completion 2020-07-14 27 sitesOther conditions: Relapsed and Refractory Multiple MyelomaView official trial listing → -
Terminated NCT NCT03520985
Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma
Not yet reported Swiss Cancer Institute 34 participants Est. completion 2021-02-03 16 sites Stand-aloneOther conditions: Refractory Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT03539744
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
Not yet reported AbbVie 265 participants Est. completion 2027-11 180 sitesOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT03567616
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Not yet reported AbbVie 8 participants Est. completion 2020-06-18 11 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT03582033
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Not yet reported Seagen Inc. 83 participants Est. completion 2023-11-09 13 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT03590652
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
Not yet reported University of California, San Diego 23 participants Est. completion 2025-07-02 4 sites Stand-aloneOther conditions: Relapsed/Refractory Multiple MyelomaView official trial listing → -
Status unknown NCT NCT03601624
Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans
Not yet reported Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado 18 participants Est. completion 2020-07-30 1 site Stand-aloneOther conditions: Multiple Myeloma in Relapse, Multiple Myeloma Progression, Refractory Multiple MyelomaView official trial listing → -
Completed NCT NCT03601806
Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection
Not yet reported AIDS Malignancy Consortium 26 participants Est. completion 2025-04-10 3 sites Stand-aloneOther conditions: Human Immunodeficiency Virus 1 Positive, Skin Kaposi SarcomaView official trial listing → -
Completed NCT NCT03651128
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Not yet reported Celgene 386 participants Est. completion 2026-04-13 62 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Withdrawn NCT NCT03657420
Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Not yet reported Massachusetts General Hospital Est. completion 2024-09-30 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT03683277
IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic
Not yet reported Intergroupe Francophone du Myelome 26 participants Est. completion 2023-02-10 28 sites Stand-aloneOther conditions: Multiple Myeloma, Relapsed and Refractory Multiple Myeloma, Genetic ConditionView official trial listing → -
Completed NCT NCT03713294
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
Not yet reported Mayo Clinic 37 participants Est. completion 2024-11-14 1 site Stand-aloneOther conditions: Refractory Plasma Cell MyelomaView official trial listing → -
Active, not recruiting NCT NCT03715478
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
Not yet reported, Not yet reported Canadian Myeloma Research Group 120 participants Est. completion 2026-12-31 9 sites Stand-aloneOther conditions: Relapsed and/or Refractory Multiple MyelomaView official trial listing → -
No Longer Available NCT NCT03723096
Expanded Access for CC-4047
Celgene 1 siteOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT03731832
Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma
Not yet reported GWT-TUD GmbH 66 participants Est. completion 2024-04-22 11 sites Stand-aloneOther conditions: Refractory Multiple MyelomaView official trial listing → -
Completed NCT NCT03732703
Myeloma-Developing Regimens Using Genomics (MyDRUG)
Not yet reported, Not yet reported Multiple Myeloma Research Consortium 103 participants Est. completion 2024-12-31 16 sites Stand-aloneOther conditions: Relapsed Refractory Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT03756896
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
Not yet reported Emory University 29 participants Est. completion 2026-06-30 1 site Stand-aloneOther conditions: Plasma Cell MyelomaView official trial listing → -
Available NCT NCT03763370
Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma
GlaxoSmithKlineOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT03798314
Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma
Not yet reported Mayo Clinic 3 participants Est. completion 2021-09-15 2 sites Stand-aloneOther conditions: Recurrent Nervous System Lymphoma, Recurrent Primary Vitreoretinal DLBCL, Refractory Nervous System Lymphoma, Refractory Primary Vitreoretinal DLBCLView official trial listing → -
Completed NCT NCT03828292
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
Not yet reported GlaxoSmithKline 15 participants Est. completion 2024-09-05 4 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Withdrawn NCT NCT03841565
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Not yet reported Academic and Community Cancer Research United Est. completion 2022-02-09 5 sites Stand-aloneOther conditions: Recurrent Plasma Cell MyelomaView official trial listing → -
Completed NCT NCT03910244
Pomalidomide for the Treatment of Bleeding in HHT
Not yet reported The Cleveland Clinic 145 participants Est. completion 2023-09-08 14 sites Stand-aloneOther conditions: Telangiectasia, Hereditary HemorrhagicView official trial listing → -
Completed NCT NCT03959358
A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders
Not yet reported University Health Network, Toronto 10 participants Est. completion 2022-10-07 1 site Stand-aloneOther conditions: Multiple Myeloma, AmyloidosisView official trial listing → -
Completed NCT NCT03984097
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Not yet reported Takeda 50 participants Est. completion 2026-03-25 9 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT04045795
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Not yet reported Sanofi 56 participants Est. completion 2024-03-27 14 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT04094961
Ixazomib + Pomalidomide + Dexamethasone In MM
Not yet reported, Not yet reported Omar Nadeem, MD 52 participants Est. completion 2027-01-01 1 site Stand-aloneOther conditions: Multiple Myeloma, Multiple Myeloma in RelapseView official trial listing → -
Active, not recruiting NCT NCT04108195
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Not yet reported Janssen Research & Development, LLC 290 participants Est. completion 2027-04-07 24 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT04124497
A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients
Not yet reported Fondazione EMN Italy Onlus 45 participants Est. completion 2027-07-01 15 sites Stand-aloneOther conditions: Multiple Myeloma, Deletion 17P SyndromeView official trial listing → -
Active, not recruiting NCT NCT04126200
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Not yet reported, Not yet reported GlaxoSmithKline 208 participants Est. completion 2027-03-11 38 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT04150965
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Not yet reported, Not yet reported Multiple Myeloma Research Consortium 14 participants Est. completion 2024-08-30 10 sites Stand-aloneOther conditions: Multiple Myeloma, Relapsed Refractory Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT04162210
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Not yet reported GlaxoSmithKline 325 participants Est. completion 2027-03-11 136 sitesOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT04176718
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Not yet reported Andrew Yee, MD 44 participants Est. completion 2028-05 3 sites Stand-aloneOther conditions: Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, RelapseView official trial listing → -
Active, not recruiting NCT NCT04181827
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
Not yet reported Janssen Research & Development, LLC 419 participants Est. completion 2027-03-31 88 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT04191616
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
Not yet reported Amgen 54 participants Est. completion 2024-10-01 46 sites Stand-aloneOther conditions: Relapsed or Refractory Multiple MyelomaView official trial listing → -
Terminated NCT NCT04243109
Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib
Not yet reported Maimónides Biomedical Research Institute of Córdoba 6 participants Est. completion 2019-05-07 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT04270175
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Not yet reported Weill Medical College of Cornell University 15 participants Est. completion 2028-01 4 sites Stand-aloneOther conditions: Amyloid, AL Amyloidosis, Refractory AL AmyloidosisView official trial listing → -
Status unknown NCT NCT04287855
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
Not yet reported Poitiers University Hospital 82 participants Est. completion 2026-04-15 1 site Stand-aloneOther conditions: Multiple Myeloma in Relapse, Multiple Myeloma, RefractoryView official trial listing → -
Active, not recruiting NCT NCT04302324
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Not yet reported Weill Medical College of Cornell University 11 participants Est. completion 2027-12-28 1 site Stand-aloneOther conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple MyelomaView official trial listing → -
Terminated NCT NCT04305444
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Not yet reported Zhejiang DTRM Biopharma 55 participants Est. completion 2024-12-31 8 sites Stand-aloneOther conditions: Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Richter's TransformationView official trial listing → -
Withdrawn NCT NCT04355039
INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Not yet reported Medical College of Wisconsin Est. completion 2024-07-01 Stand-aloneOther conditions: Refractory Multiple Myeloma, Relapse Multiple MyelomaView official trial listing → -
Withdrawn NCT NCT04392648
A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Not yet reported Teva Branded Pharmaceutical Products R&D LLC Est. completion 2023-11-10 Stand-aloneOther conditions: Relapsed and/or Refractory Multiple MyelomaView official trial listing → -
Completed NCT NCT04458831
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Sanofi 583 participants Est. completion 2026-02-23 129 sitesOther conditions: Plasma Cell MyelomaView official trial listing → -
Active, not recruiting NCT NCT04484623
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Not yet reported GlaxoSmithKline 302 participants Est. completion 2029-06-25 122 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT04577755
Pomalidomide Treatment in Patients With Kaposi Sarcoma
Not yet reported National Cancer Institute (NCI) 45 participants Est. completion 2026-10-01 15 sites Stand-aloneOther conditions: Skin Kaposi SarcomaView official trial listing → -
Withdrawn NCT NCT04584307
Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant
Not yet reported Natalie Callendar Est. completion 2024-12 Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT04667663
CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
Not yet reported Cancer Trials Ireland 16 participants Est. completion 2026-04-30 3 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT04700176
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Not yet reported Hackensack Meridian Health 1 participants Est. completion 2023-11-15 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT04722146
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Not yet reported Janssen Research & Development, LLC 140 participants Est. completion 2027-10-13 27 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Status unknown NCT NCT04762745
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
Not yet reported, Not yet reported Sun Yat-sen University 56 participants Est. completion 2023-02 1 site Stand-aloneOther conditions: Relapsed, Refractory, Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT04764942
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Not yet reported, Not yet reported Mayo Clinic 39 participants Est. completion 2027-12-17 1 site Stand-aloneOther conditions: Recurrent Multiple Myeloma, Refractory Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT04790474
Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib
Not yet reported Tel-Aviv Sourasky Medical Center 61 participants Est. completion 2028-01-01 7 sites Stand-aloneOther conditions: Multiple Myeloma in Relapse, Refractory Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT04802161
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
Not yet reported National Cancer Institute (NCI) 49 participants Est. completion 2027-04-25 11 sites Stand-aloneOther conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative NeoplasmView official trial listing → -
Active, not recruiting NCT NCT04835129
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Not yet reported Medical College of Wisconsin 28 participants Est. completion 2027-06-01 2 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT04843579
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
Not yet reported Weill Medical College of Cornell University 4 participants Est. completion 2022-12-30 2 sites Stand-aloneOther conditions: Myeloma Multiple, Myeloma, Refractory Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT04850599
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
Not yet reported OHSU Knight Cancer Institute 5 participants Est. completion 2029-02-21 1 site Stand-aloneOther conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaView official trial listing → -
Active, not recruiting NCT NCT04883242
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Not yet reported University of Washington 30 participants Est. completion 2031-12-31 1 site Stand-aloneOther conditions: Recurrent Multiple Myeloma, Refractory Multiple MyelomaView official trial listing → -
Terminated NCT NCT04892446
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Not yet reported Gilead Sciences 36 participants Est. completion 2024-04-25 22 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT04895410
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
Not yet reported AbbVie 8 participants Est. completion 2022-06-24 32 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Terminated NCT NCT04895917
Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis
Not yet reported Fondazione IRCCS Policlinico San Matteo di Pavia 27 participants Est. completion 2025-01-15 3 sites Stand-aloneOther conditions: AL AmyloidosisView official trial listing → -
Active, not recruiting NCT NCT04925193
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Not yet reported University of Colorado, Denver 18 participants Est. completion 2026-11 1 site Stand-aloneOther conditions: Multiple Myeloma in RelapseView official trial listing → -
Status unknown NCT NCT04941937
Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM
Not yet reported Juan Du 90 participants Est. completion 2025-12-30 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Status unknown NCT NCT04942067
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Not yet reported, Not yet reported Ascentage Pharma Group Inc. 108 participants Est. completion 2024-12-01 3 sites Stand-aloneOther conditions: Multiple Myeloma, AmyloidosisView official trial listing → -
Status unknown NCT NCT04989140
Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
Not yet reported Peking Union Medical College Hospital 60 participants Est. completion 2024-07-26 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT05028348
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
Not yet reported European Myeloma Network B.V. 117 participants Est. completion 2029-03 20 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT05050097
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Not yet reported Janssen Research & Development, LLC 166 participants Est. completion 2027-04-07 31 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Withdrawn NCT NCT05050305
Marizomib Central Nervous System (CNS)
Not yet reported Dana-Farber Cancer Institute Est. completion 2027-12 2 sites Stand-aloneOther conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, RefractoryView official trial listing → -
Status unknown NCT NCT05066607
Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy
Not yet reported Intergroupe Francophone du Myelome 46 participants Est. completion 2026-03 15 sites Stand-aloneOther conditions: AL AmyloidosisView official trial listing → -
Active, not recruiting NCT NCT05083169
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Not yet reported Janssen Research & Development, LLC 587 participants Est. completion 2028-09-15 176 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Withdrawn NCT NCT05183139
A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
Not yet reported Takeda Est. completion 2026-12-31 Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Withdrawn NCT NCT05205252
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
Not yet reported, Not yet reported Epizyme, Inc. Est. completion 2023-07-05 3 sitesOther conditions: Relapsed Hematologic Malignancy, Refractory Hematologic MalignancyView official trial listing → -
Status unknown NCT NCT05236621
A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Not yet reported Qilu Pharmaceutical Co., Ltd. 85 participants Est. completion 2023-12 23 sites Stand-aloneOther conditions: Multiple Myeloma, Recurrent or RefractoryView official trial listing → -
Active, not recruiting NCT NCT05259839
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Not yet reported AbbVie 283 participants Est. completion 2033-09 49 sites Stand-aloneOther conditions: Relapsed/Refractory Multiple MyelomaView official trial listing → -
Terminated NCT NCT05288062
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Not yet reported Mayo Clinic 17 participants Est. completion 2024-07-25 4 sites Stand-aloneOther conditions: Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell MyelomaView official trial listing → -
Status unknown NCT NCT05298683
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Not yet reported Hellenic Society of Hematology 108 participants Est. completion 2026-01 6 sites Stand-aloneOther conditions: Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Paraproteinemias, Blood Protein Disorders, Hematologic DiseasesView official trial listing → -
Status unknown NCT NCT05378971
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
Not yet reported LanZhou University 15 participants Est. completion 2025-05-30 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Status unknown NCT NCT05390749
Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL
Not yet reported Peking Union Medical College Hospital 50 participants Est. completion 2026-04-01 3 sites Stand-aloneOther conditions: Primary Central Nervous System LymphomaView official trial listing → -
Active, not recruiting NCT NCT05405166
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
Not yet reported Sanofi 531 participants Est. completion 2027-10-22 128 sites Stand-aloneOther conditions: Plasma Cell Myeloma RecurrentView official trial listing → -
Withdrawn NCT NCT05408026
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
Not yet reported, Not yet reported Alliance Foundation Trials, LLC. Est. completion 2026-02 Stand-aloneOther conditions: Relapsed or Refractory Multiple MyelomaView official trial listing → -
Status unknown NCT NCT05432414
PVd Versus Vd in NDMM Patients With RI
Not yet reported RenJi Hospital 79 participants Est. completion 2024-07-31 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT05438043
A Study of Daratumumab
Not yet reported Janssen Research & Development, LLC 213 participants Est. completion 2029-01-31 92 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT05451771
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Not yet reported, Not yet reported Columbia University 53 participants Est. completion 2027-09 5 sitesOther conditions: AL AmyloidosisView official trial listing → -
Active, not recruiting NCT NCT05455320
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Not yet reported Janssen Research & Development, LLC 864 participants Est. completion 2028-05-25 216 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Status unknown NCT NCT05478993
Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement
Not yet reported Peking University People's Hospital 21 participants Est. completion 2025-07-10 2 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Status unknown NCT NCT05509374
Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone
Not yet reported Samsung Medical Center 33 participants Est. completion 2024-06-30 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT05555329
Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study
Not yet reported Amsterdam UMC, location VUmc 12 participants Est. completion 2024-02-14 1 site Stand-aloneOther conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, RefractoryView official trial listing → -
Terminated NCT NCT05556616
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
Not yet reported Teva Branded Pharmaceutical Products R&D LLC 15 participants Est. completion 2024-06-04 21 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT05556798
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
Not yet reported Memorial Sloan Kettering Cancer Center 9 participants Est. completion 2027-10 7 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT05572515
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Not yet reported Janssen Research & Development, LLC 614 participants Est. completion 2031-08-31 211 sites Stand-aloneOther conditions: Relapsed or Refractory Multiple MyelomaView official trial listing → -
Not yet recruiting NCT NCT05581875
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
Not yet reported, Not yet reported Hellenic Society of Hematology 48 participants Est. completion 2026-10-31 Stand-aloneOther conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasms, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease, Neoplasms, Plasma CellView official trial listing → -
Enrolling by invitation NCT NCT05669989
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Not yet reported Sanofi 70 participants Est. completion 2028-11-30 37 sites Stand-aloneOther conditions: Plasma Cell MyelomaView official trial listing → -
Terminated NCT NCT05675319
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
Not yet reported Universitätsklinikum Hamburg-Eppendorf 28 participants Est. completion 2025-03-21 30 sitesOther conditions: Multiple MyelomaView official trial listing → -
Status unknown NCT NCT05809180
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
Not yet reported The First Affiliated Hospital of Soochow University 35 participants Est. completion 2026-07-03 1 site Stand-aloneOther conditions: Diffuse Large B Cell LymphomaView official trial listing → -
Active, not recruiting NCT NCT05911321
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
Not yet reported UNC Lineberger Comprehensive Cancer Center 6 participants Est. completion 2028-03-26 2 sites Stand-aloneOther conditions: Multiple Myeloma, Relapse, Refractory, Aging, Co-morbidityView official trial listing → -
Status unknown NCT NCT06058689
A Pilot Bioequivalence Study of Pomalidomide
Not yet reported Megalabs 10 participants Est. completion 2025-03-15 1 site Stand-aloneOther conditions: Bioequivalence StudyView official trial listing → -
Active, not recruiting NCT NCT06158841
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Not yet reported AbbVie 421 participants Est. completion 2027-12 166 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT06163040
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb 7 participants Est. completion 2025-03-17 4 sitesOther conditions: Relapsed or Refractory Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT06208150
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Not yet reported Janssen Research & Development, LLC 838 participants Est. completion 2028-12-31 242 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Completed NCT NCT06212596
Selinexor, Cyclophosphamide and Prednisone in Myeloma
Not yet reported University of Leeds 66 participants Est. completion 2023-11-14 13 sites Stand-aloneOther conditions: Relapsed or Refractory Multiple MyelomaView official trial listing → -
Withdrawn NCT NCT06232707
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Not yet reported Celgene Est. completion 2030-09-21 170 sitesOther conditions: Multiple MyelomaView official trial listing → -
Status unknown NCT NCT06255847
Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM
Not yet reported Shanxi Bethune Hospital 43 participants Est. completion 2025-06-15 1 site Stand-aloneOther conditions: Multiple Myeloma in RelapseView official trial listing → -
Active, not recruiting NCT NCT06413498
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Not yet reported Kite, A Gilead Company 452 participants Est. completion 2031-07 117 sitesOther conditions: Multiple MyelomaView official trial listing → -
Status unknown NCT NCT06455748
Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study
Not yet reported Yongyong MA 20 participants Est. completion 2025-03-01 1 site Stand-aloneOther conditions: Amyloid Light-chain AmyloidosisView official trial listing → -
Not yet recruiting NCT NCT06594432
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
Not yet reported The First Affiliated Hospital with Nanjing Medical University 40 participants Est. completion 2027-06 1 siteOther conditions: Diffuse Large B Cell Lymphoma (DLBCL)View official trial listing → -
Active, not recruiting NCT NCT06660498
Pomalidomide as an Immune-enhancing Agent for the Control of HIV
Not yet reported, Not yet reported University of Aarhus 32 participants Est. completion 2027-03-31 2 sitesOther conditions: HIV-1 InfectionView official trial listing → -
Not yet recruiting NCT NCT06742138
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
Not yet reported Qilu Pharmaceutical Co., Ltd. 284 participants Est. completion 2028-12 Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Status unknown NCT NCT06832228
Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
Not yet reported Zhejiang Cancer Hospital 30 participants Est. completion 2026-09-01 1 site Stand-aloneOther conditions: Diffuse Large B-cell Lymphoma (DLBCL)View official trial listing → -
Active, not recruiting NCT NCT06924424
Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma
Not yet reported Peking University People's Hospital 105 participants Est. completion 2027-06-30 2 sites Stand-aloneOther conditions: Multiple Myeloma, NeoplasmsView official trial listing → -
Active, not recruiting NCT NCT06956170
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Not yet reported GlaxoSmithKline 21 participants Est. completion 2029-06-25 13 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Not yet recruiting NCT NCT07015021
The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients
Not yet reported The First Affiliated Hospital of Soochow University 72 participants Est. completion 2026-09-30 Stand-aloneOther conditions: Multiple Myeloma, Carfilzomib, Daratumumab, PomalidomideView official trial listing → -
Completed NCT NCT07018401
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
Massachusetts General Hospital 62 participants Est. completion 2026-06-01 11 sitesOther conditions: Hereditary Hemorrhagic Telangiectasia (HHT)View official trial listing → -
Active, not recruiting NCT NCT07150104
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
Not yet reported, Not yet reported GlaxoSmithKline 14 participants Est. completion 2027-03-11 10 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Not yet recruiting NCT NCT07441954
Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma
Not yet reported, Not yet reported Institute of Hematology & Blood Diseases Hospital, China 53 participants Est. completion 2029-12-31 Stand-aloneOther conditions: Indolent LymphomaView official trial listing → -
Not yet recruiting NCT NCT07560449
QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms
Not yet reported Qilu Pharmaceutical Co., Ltd. 162 participants Est. completion 2030-06 Stand-aloneOther conditions: Malignant Plasma Cell NeoplasmsView official trial listing → -
Not yet recruiting NCT NCT07569757
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 260 participants Est. completion 2030-12 49 sitesOther conditions: Multiple MyelomaView official trial listing → -
Not yet recruiting NCT NCT07609446
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
The First Affiliated Hospital of Soochow University 30 participants Est. completion 2027-12-31 1 siteOther conditions: Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Mantle Cell LymphomaView official trial listing → -
Not yet recruiting NCT NCT07637526
Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma
PETHEMA Foundation 100 participants Est. completion 2027-12-31Other conditions: Relapse Multiple MyelomaView official trial listing → -
Completed NCT NCT07689006
Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens
Bristol-Myers Squibb 341 participants Est. completion 2025-03-28 1 siteOther conditions: Relapsed/Refractory Multiple MyelomaView official trial listing → -
Completed NCT NCT07694011
Bioequivalence Study Comparing Two Pomalidomide 4 mg Capsule Formulations in Healthy Male Subjects
Not yet reported Knight Therapeutics (USA) Inc 34 participants Est. completion 2025-02-07 1 site Stand-aloneOther conditions: Pomalidomide Bioequivalence Study in Healthy VolunteersView official trial listing → -
Not yet recruiting NCT NCT07720843
TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)
Not yet reported Montefiore Medical Center 50 participants Est. completion 2032-03 Stand-aloneOther conditions: Relapse Multiple Myeloma, Refractory Multiple MyelomaView official trial listing → -
Not yet recruiting NCT NCT07728188
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Not yet reported AbbVie 520 participants Est. completion 2033-02 66 sites Stand-aloneOther conditions: Relapsed or Refractory Multiple MyelomaView official trial listing → -
Not yet recruiting NCT NCT07748689
Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Not yet reported Polish Myeloma Consortium 228 participants Est. completion 2033-03 Stand-aloneOther conditions: Relapsed / Refractory Multiple MyelomaView official trial listing → -
Not yet recruiting NCT NCT07757412
Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.
Not yet reported Odense University Hospital 50 participants Est. completion 2032-01-01 9 sites Stand-aloneOther conditions: Multiple Myeloma ProgressionView official trial listing → -
Not yet recruiting NCT NCT07760610
Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response
Not yet reported The First Hospital of Jilin University 27 participants Est. completion 2029-07 Stand-aloneOther conditions: Diffuse Large B-Cell Lymphoma (DLBCL)View official trial listing → -
Not yet recruiting NCT NCT07831122
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
Not yet reported Canadian Myeloma Research Group 108 participants Est. completion 2033-03 7 sites Stand-aloneOther conditions: Relapsed Refractory Multiple Myeloma (RRMM)View official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.